HLB is taking control of changes of the future in various business fields, with
constant efforts and passion.
LSK BIOPHARMA ANNOUNCES STARTING OF SITE INITIATION VISITS IN THE U.S. FOR ITS PHASE 3 GASTRIC CANCER TRIAL STUDYING APATINIB
SALT LAKE CITY, USA, May 16, 2017 – LSK BioPharma (LSKB, Company) announced today that it has started Site Initiation Visits (SIVs) for clinical sites in the United States for its global apatinib phase 3 gastric cancer trial. The Company has already initiated sites in South Korea, Japan, and Taiwan, and is currently enrolling patients. LSKB expects to open sites in a total of 12 countries in Asia, North America, and Europe over the next several months.
“We are excited to bring this important trial to the US,” noted Dr. Sung Chul Kim, President of LSK BioPharma, “Although the clinical need for apatinib in gastric cancer is well known in Asia, we believe the drug will bring an important benefit to such patients in the US and Europe.”
The SIV is the last important step wherein the Company and CRO confirm that the site is prepared to start enrolling patients in the clinical trial.